Open an account

IO Biotech

IOBTQ · NASDAQ

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About IOBTQ

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Employees
80
Headquarters
COPENHAGEN
Listed
Nov 5, 2021
Sector
Health Care
Industry
Biotechnology
Website
iobiotech.com

IOBTQ key statistics

Market cap
7.20K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
6.76K
Volume
3
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0203
52 Week low
$0.00

IO Biotech (IOBTQ) at a glance

IO Biotech (IOBTQ) last traded at $0.0001, with a market cap of 7.20K and a price-to-earnings ratio of 0.00.

Volume so far is 3 shares, below the average of 6.76K shares a day.

Over the past year IO Biotech has ranged from $0.00 to $0.0203, and now sits 0% of the way up that range.

IO Biotech met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY25 it reported -$0.13 per share against an estimate of -$0.3337.

IOBTQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 22.4% on average.

  1. Q4 FY23: reported -$0.40 per share against an estimate of -$0.3996
  2. Q1 FY24: reported -$0.30 per share against an estimate of -$0.3708
  3. Q2 FY24: reported -$0.31 per share against an estimate of -$0.3605
  4. Q3 FY24: reported -$0.36 per share against an estimate of -$0.2961
  5. Q4 FY24: reported -$0.48 per share against an estimate of -$0.4017
  6. Q1 FY25: reported -$0.34 per share against an estimate of -$0.3914
  7. Q2 FY25: reported -$0.35 per share against an estimate of -$0.3667
  8. Q3 FY25: reported -$0.13 per share against an estimate of -$0.3337

IOBTQ news

  • Press releaseGlobe Newswire

    Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition

Similar companies

Companies in the same industry as IO Biotech

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.